SPECIAL PURPOSE BIOCHEMICALS

Antibiotics

Glycosidase Inhibitors

Steroids

Miscellaneous

ANTIBIOTICS

EI-113
Acivicin (U-42126)

CA-100
Antibiotic A-23187 (Calcimycin)

A-150
Alamethacin (U-22324)
[27061-78-5] Storage: 0°C, mixture of alamethicin homologs
Membrane permeabilizing antibiotic¹. Applications include increasing [³²P] incorporation into phosphatidylinositol 4-phosphate² and permeabilization of sarcoplasmic reticulum vesicles³.
5 mg
25 mg

A-190
Clindamycin·HCl (U-21251F)
7(S)-Chloro-7-deoxylincomycin
MW=461.4 [21462-39-5] Storage: 0°C
Active against gram-positive bacteria. Clindamycin binds to the 50S subunit of bacterial ribosomes and supresses protein synthesis⁴.
20 mg
100 mg

A-192
Clindamycin phosphate (U-28508E)
7(S)-Chloro-7-deoxylincomycin
MW=505.0 [24729-96-2] Storage: 0°C
20 mg
100 mg

A-230
Decoyinine (U-7984)

A-240
Lincomycin (U-10149A)
98%, MW=406.5 [154-21-2] Storage: 0°C
Active against gram-positive bacteria. Lincomycin binds to the 50S subunit of bacterial ribosomes and supresses protein synthesis.
1 g
5 g

A-245
Lomofungin (U-24792)
98%, MW=314.3 [26786-84-5] Storage: 0°C
Broad-spectrum antibiotic. Lomafungin rapidly and efficiently inhibits RNA synthesis⁵.
10 mg
50 mg

A-249
Mycophenolic acid
98%, MW=320.3 [24280-93-1] Storage: -20°C
Antiviral⁶ and immunosuppressive activity⁷. Clinically useful antipsoriatic agent⁸. Mycophenolic acid prodrugs are effective in rheumatoid arthritis⁹ and for the prevention of organ transplant rejection¹⁰. Mechanism of action is inhibition of inosine-5'-monophosphate dehydrogenase¹¹.
100 mg
500 mg

A-251
Neamine (U-5214)
97%, MW=322.4 [3947-65-7] Storage: 0°C
Component of the aminoglycoside antibiotic complex neomycin. Marginally effective at increasing permeability in PI-containing membranes¹². Increases phosphatidylinositol 4-phosphate kinase activity selectively over PI kinase activity².
20 mg
100 mg

EI-180
Neomycin Sulfate

GR-312
Puromycin 2HCl

A-260
Puromycin aminonucleoside
3'-Amino-3'-deoxy-N,N-dimethyladenosine
98%, MW=294.3 [58-60-6] Storage: -20°C
A puromycin analog which does not inhibit protein synthesis or induce apoptosis¹³. It is a glomerular epithelial cell toxin which may be used to induce nephropathy in laboratory animals¹⁴.
50 mg
500 mg

A-280
Spectinomycin?HCl (U-18409AE)
98%, MW=405.3 [21736-83-4] Storage: 0°C
Aminocyclitol antibiotic active against gram-negative bacteria. In clinical use for gonorrhea¹⁵. Spectinomycin binds to the 30S subunit of bacterial ribosomes and supresses protein synthesis¹⁶.
10 g

A-281
Spectinomycin sulfate (U-18409E)
98%, MW=430.4, Storage: 0°C
10 g

A-282
Streptolydigin (U-5481)
98%, MW=600.7 [7229-50-7] Storage: 0°C
Active against some gram-positive bacteria. Inhibits assembly of the RNA polymerase II transcription complex¹⁷. Inhibits RNA polymerase III transcription¹⁸.

EI-138
Streptozotocin (U-9889)
98%, MW=265.2 [18883-66-4] Storage:-20?br> Antineoplastic agent¹⁹. A useful agent for the induction of diabetes in laboratory animals^20,21.
1 g
5 g

KC-140
Valinomycin

1. D. Brewer et al. Can. J. Microbiol. 1987 33 619

2. E. Quist et al. Arch. Biochem. Biophys. 1989 271 21

3. M. Nakagawa and J.H. Willner J. Cyclic. Nucleotide Protein Phosphor. Res. 1986 11 237

4. F. Reusser Antimicrobial Agents Chemother. 1975 7 32

5. M. Kopecka and V. Farkas J. Gen. Microbiol. 1979 110 453

6. R.H. Williams et al. J. Antibiot. 1968 21 463

7. A.C. Allison et al. Immunol. Rev. 1993 136 5

8. W.W. Epinette et al. J. Am. Acad. Dermatol. 1987 17 962

9. R. Goldblum Clin. Exp. Rheumatol. 1993 11 S117

10. R.D. Ensley et al. Transplantation 1993 56 75

11. S.B. Carter et al. Nature 1969 223 848

12. S. Au et al. Biochim. Biophys. Acta 1987 902 80

13. S.C. Chow et al. Exp. Cell Res. 1995 216 149

14. H. Trachtman et al. J. Am. Soc. Nephrol. 1995 5 1811

15. W.W. Karney et al. N. Eng. J. Med. 1977 296 889

16. R.N. Brogden and G.S. Avery Drugs 1972 3 314

17. K. Logan et al. DNA 1989 8 595

18. K. Logan and S. Ackerman DNA 1988 7 483

19. R.A. Bennett and A.E. Pegg Cancer Res. 1981 41 2786

20. M. Valentovic and W.C. Lubawy Diabetes 1983 32 846

21. R.T. Holman et al. Proc. Natl. Acad. Sci. USA 1983 80 2375

GLYCOSIDASE INHIBITORS

S-105
Australine·HCl
98%, MW=225.5, Storage: 0°C
Inhibits amyloglucosidase (an exo-1,4--glucosidase) and glycoprotein processing enzyme glucosidase I (selectively over glucosidase II)¹.
1 mg
5 x 1 mg

S-106
Bromoconduritol
6-Bromo-3,4,5-trihydroxycyclohex-1-ene
99%, mixed isomers, MW=209.0 [42014-74-4] Storage: 0°C
Inhibits mammalian -glucosidase II selectively over -glucosidase I².
10 mg
50 mg

S-107
Castanospermine
99%, MW=189.2 [79831-76-8] Storage: 0°C
Potent inhibitor of - and -glucosidases^3,4,5. Inhibits HIV infectivity^6,7,8. Inhibits thyroglobulin secretion⁹. Antitumor activity¹⁰.
10 mg
50 mg

S-104
Conduritol B epoxide
97%, MW=162.1 [6090-95-5] Storage: 0°C
A potent, irreversible inhibitor of various plant -glucosidases¹¹ and mammalian glucocerebrosidase^12,13. Has been employed in in vitro¹⁴ and animal¹⁵ models for Gaucher's disease.
5 mg
25 mg

S-108
Deoxyfuconojirimycin
99%, MW=147.2, Storage: 0°C
A potent and selective inhibitor of -L-fucosidases¹⁶.
1 mg
5 mg

S-109
Deoxymannojirimycin·HCl
99%, MW=199.6 [84444-90-6] Storage: 0°C
Inhibits -mannosidases¹⁷.
1 mg
5 mg

S-110
Deoxynojirimycin·HCl
99%, MW=199.6 [19130-96-2] Storage: 0°C
Inhibits -glucosidase I and II^18,19.
1 mg
5 mg

S-113
N-Ethyldeoxynojirimycin
99%, MW=191.2, Storage: 0°C
Inhibits HIV cytopathicity²⁰.
1 mg
5 mg

S-114
Kifunensine
98%, MW=232.2 [109944-15-2] Storage: -20°C
Inhibits -mannosidase. Inhibits asparagine-linked oligosaccharide processing. Immunomodulator^21-24.
1 mg
5 mg

S-115
Mannostatin A·HCl
98%, MW=201.7 [102822-56-0] Storage: -20°C
Potent and effective inhibitor of Golgi processing mannosidase II^24,25.
1 mg
5 x 1 mg

S-112
Swainsonine
99%, MW=173.2 [72741-87-8] Storage: 0°C
A potent -mannosidase inhibitor^26,27. Immunomodulator^28,29,30.
1 mg
5 mg

1. R.J. Molyneux et al. J. Nat. Prod. 1988 51 1198

2. R. Datema et al. Proc. Natl. Acad. Sci. USA 1982 79 6787

3. R. Saul et al. Arch. Biochem. Biophys. 1984 230 6368

4. Y.T. Pan et al. Biochemistry 1983 22 3975

5. R.T. Schwartz and R. Datema Trends Biochem. Sci. 1984 9 32

6. R.A. Gruters et al. Nature 1987 330 74

7. B.D. Walker et al. Proc. Natl. Acad. Sci. USA 1987 84 8120

8. R.M. Ruprecht et al. AIDS 1991 4 48

9. J.-L. Franc et al. Endocrinology 1990 126 1464

10. G.K. Ostrander et al. Cancer Res. 1988 48 1091

11. G. Legler Hoppe-Seyler's Z. Physiol. Chem. 1970 351 25

12. A. Hara and N.S. Radin Biochim. Biophys. Acta 1979 582 412

13. S.C. Datta and N.S. Radin Biochem. Biophys. Res. Commun. 1988 152 155

14. D.S. Newburg et al. Biochim. Biophys. Acta 1986 877 121

15. M.C. Stephens et al. J. Neurochem. 1978 30 1023

16. G.W.J. Fleet et al. J. Chem. Soc. Chem. Commun. 1985 841

17. J. Bischoff et al. J. Biol. Chem. 1986 261 4766

18. V. Gross et al. J. Biol. Chem. 1983 258 12203

19. U. Fuhmann et al. Biochim. Biophys. Acta 1985 825 95

20. G.W.J. Fleet et al. FEBS Lett. 1988 237 128

21. M. Iwami et al. J. Antibiot. 1987 40 612

22. A.D. Elbein et al. Arch. Biochem. Biophys. 1991 288 177

23. S. Chandrasekaran et al. J. Biol. Chem. 1994 269 3356

24. A.D. Elbein FASEB J. 1991 5 3055

25. J.E. Tropea et al. Biochemistry 1990 29 10062

26. J.R. Winkler and H.L. Segal J. Biol. Chem. 1984 259 15369

27. J.E Tropea et al. J. Biol. Chem. 1988 263 4309

28. D.A. Granato and J.R. Neeser Mol. Immunol. 1987 24 849

29. S.L. White et al. Biochem. Biophys. Res. Commun. 1988 150 615

30. M.J. Humphries et al. Cancer Res. 1988 48 1410

STEROIDS

S-200
3-(2-Diethylaminoethoxy)-androstenone·HCl (U-18666A)
99%, MW=424.1, Storage: RT
Inhibits intracellular transport of LDL-cholesterol in CHO cells¹. Inhibits cholesterol biosynthesis by inhibition of 2,3-oxidosqualene-lanosterol cyclase activity².
10 mg
50 mg

EI-126
Dexamethasone

S-250
6-Fluorotestosterone (U-11207)
99%, MW=306.4 [1597-68-8] Storage: RT
Nonaromatizable androgen, as effective as testosterone³.
5 mg
25 mg

S-520
Melengestrol acetate (U-21240)
99%, MW=396.5 [2919-66-6] Storage: RT
Antineoplastic. Progestogen.
200 mg
1 g

W-300
Mibolerone (U-10997)
99%, MW=302.5 [3704-09-4] Storage: RT
Anabolic steroid.
Controlled substance. Schedule 3. information.
100 mg
500 mg

S-510
Mifepristone (RU 486)
99%, MW=429.6 [84371-65-3] Storage: -20°C
Progesterone receptor antagonist⁵.
25 mg
100 mg

S-620
Pregnenolone-16-carbonitrile (U-14975)
99%, MW=341.5 [1434-54-4] Storage: 0°C
Cytochrome P-450 inducer^6,7. Activates transcription of the PCN1 gene⁸.
50 mg
250 mg

ST-391
U-73122

1. L. Liscum and J. Faust J. Biol. Chem. 1989 264 11796

2. R.C. Sexton et al. Biochemistry 1983 22 5687

3. P. Yahr and S.A. Gerling Horm. Behav. 1978 10 128

4. J.A. Campbell et al. Steroids 1963 1 317

5. M. Rauch et al. Eur. J. Biochem. 1985 148 213

6. J.P. Hardwick et al. J. Biol. Chem. 1983 258 10182

7. P.B. Watkins et al. Proc. Natl. Acad. Sci. USA 1985 82 6310

8. F.J. Gonzalez et al. Mol. Cell. Biol. 1986 6 2969

MISCELLANEOUS

T-105
N₁, N₁₂-Diethylspermine?HCl
98%, MW=404.3, Storage: -20°C
Antineoplastic activity. Inhibits polyamine synthesis¹.
10 mg
50 mg

T-112
Alrestatin
1,3-Dioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid
99%, MW=255.2 [51411-04-2] Storage: RT
Aldose reductase inhibitor².
10 mg
50 mg

T-113
Parthenolide
97%, MW=248.3 [20554-84-1] Storage: -20°C
Sesquiterpene lactone and active principle of feverfew (Chrysanthemum parthenium) which is widely used as a herbal remedy for arthritis and migraine. Has anti-inflammatory, antisecretory and spasmolytic activity. Inhibits the release of various mediators^3,4,5 and inhibits activation of MAP kinase⁶.
50 mg
250 mg

T-114
S-[N-(3-Phenylpropyl)thiocarbamoyl]-L-cysteine
98%, MW=299.4, Storage: -20°C
Induces glutathione S-transferase. Inhibits chemical carcinogenesis⁷.
50 mg
250 mg

T-115
Thalidomide
(?-N-(2,6-Dioxo-3-piperidinyl)phthalimide
99%, MW=258.2 [50-35-1] Storage: RT
Inhibits TNF- biosynthesis⁸. Inhibits FGF-induced angiogenesis⁹. Inhibits replication of human immunodeficiency virus type I (HIV-I)¹⁰ Teratogenic sedative¹¹.
100 mg
5 x 100 mg

1. C.W. Porter et al. Biochem. J. 1990 268 207

2. L.G. Humber Prog. Med. Chem. 1987 24 299

3. W.A. Groenewegen et al. J. Pharm. Pharmacol. 1990 42 553

4. H. Sumner et al. Biochem. Pharmacol. 1992 43 2313

5. R.W. Barsby et al. J. Pharm. Pharmacol. 1992 44 737

6. D. Hwang et al. Biochem. Biophys.Res. Commun. 1996 226 810

7. G.-Q. Zheng et al. J. Med. Chem. 1992 35 185

8. W.B. Weglicki et al. Mol. Cell. Biochem. 1993 129 195

9. R.J. D'Amato et al. Proc. Natl. Acad. Sci. USA 1994 91 4082

10. S. Makonkawkeyoon et al. Proc. Natl. Acad. Sci. USA 1993 90 5974

11. H. Schumacher et al. J. Pharmacol. Exp. Therap. 1968 160 189